CANbridge Uses Boehringer Ingelheim China to Manufacture Novel Biologic

CANbridge Life Sciences, a Beijing in-licensing pharma, assigned manufacturing responsibilities for CAN-017, an ErbB3 (HER3) inhibitory antibody, to Boehringer Ingelheim China. BI currently runs a clinical-supply CMO operation at BioLab in Shanghai. It is building a $81 million biologics CMO facility in Shanghai's Zhangjiang Park that is slated to begin operations in 2017. BI is one of the first CMOs admitted to China's pilot Marketing Authorization Holder (MAH) program, which will allow, for the first time, approval of drugs that are manufactured by third parties. More details.... Share this with colleagues: // //